The power of knowledge.
The value of understanding.

**Sun 11/8**

8:00am – 12:00pm Short Course: **Hauber AB**, Bridges JFP - Conjoint Analysis – Theory & Methods [Space 3 (L0)]

8:00am – 12:00pm Short Course: **Mauskopf J**, Mullins D, **Earnshaw S** - Budget Impact Analysis I: A 6-Step Approach [Space 2 (L0)]

1:00pm – 5:00pm Short Course: **Earnshaw S**, Brogan AJ, **Wolowacz S** - Budget Impact Analysis II: Applications and Design Issues [Space 2 (L0)]

**Mon 11/9**

Poster Session I 8:45am – 2:15pm

**Poster PCV106**: Brockbank J, Wolowacz S - Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Total Knee Replacement [J3]

**Poster PSS13**: Ravasio R, Cawson MR, McBride D, Balp M, Roccia A - Budget Impact Model of Omalizumab in the Treatment of Chronic Spontaneous Urticaria in Italy [N9]

**Poster PSS23**: Graham CN, McBride D, Miles L, Kneidl J, Mollon P - Estimation of Indirect (Work-Related Productivity) Costs Associated with Moderate-to-Severe Plaque Psoriasis in Germany [N19]


**Poster PSS50**: D’Ausilio A, Aiello A, Daniel F, Graham CN, Roccia A, Toumi M - A Cost-Effectiveness Analysis of Secukinumab 300 Mg vs Current Therapies for the Treatment of Moderate to Severe Plaque Psoriasis in Italy [O13]

**Poster PSS55**: Klimes J, Mollon P, Graham CN, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J - Cost-Effectiveness Analysis of Secukinumab Compared to Ustekinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the Czech Republic [O14]


**Poster PSS66**: Edson-Heredia E, Barrows S, Masaquel C, Nikai E, Mailbris L, Puig L - The Value of Achieving Complete or Near Complete Resolution of Psoriasis [P8]


Poster Session II 3:45 – 7:45pm

**Poster PCN120**: Nash Smyth E, La E, Talbird S, Li L, Kaye JA, Lin AB, Bowman L - Treatment Patterns and Health Care Resource Use (HCRU) Associated with Repeatedly Treated Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the United Kingdom (UK) [D21]


**Poster PCN230**: Clark M, Harris NL, Martin S, Bartley K, DeBusk K, Abidoye O, Shore N - The Impact of Non-Muscle Invasive Bladder Cancer: Qualitative Research with Patients [H31]

**Poster PCN297**: Goyal RK, Davis KL, Coté I, Mounedji N, Kaye JA - Health Care Resource Use and Costs among Polycythemia Vera Patients in the United States: Results from an Observational Cohort Study [J31]

**Poster PCN324**: Hogue S, Brogan AP, DeMuro C, D'Alessio D, Balv I - Patient Reported Outcomes (PRO) in Postprogression Oncology: Implications in Health Technology Assessments (HTA) & Payer Decision Making [K24]
### Tues 11/10

**Poster Session III**
8:45am – 1:45pm


- **Poster PHP231**: Broekhuizen H, Ijzerman MJ, Hauber AB, Groothuis-Oudshoorn CG - Building a Bridge Between Clinical Evidence Research and Patient Preference Research [H30]

12:15 – 1:15pm **Educational Symposium**: Martin S, Deal LS, Fricke FU, Knight C - Rare Diseases: Navigating the Road to Approval and Access [Gold (L2)]

12:15 – 1:30pm **ISPOR Oncology Special Interest Group Meeting**: Wolowacz S, Muszbek N, Benedict A. [Space 3 (L0)]

**Poster Session IV**
3:15 – 7:15pm

- **Poster PDB1**: Ajmera MR, Sambamoorthi U - Risk of New-Onset Diabetes Associated with Concomitant Antidepressant, Inhaled Corticosteroids, and Statin Use Among Medicaid Beneficiaries with COPD [A1]

- **Poster PDB94**: Mansfield CA, Sikirica M, Pugh A, Poulos C, Martin AA, Ruiz Moran L, Morano Larragueta R - Patient Preferences for Attributes of Type 2 Diabetes Mellitus (T2DM) Treatments in Spain [C27]

- **Poster PG161**: Khan S, Zimovetz E, Healey P, Copley-Merriman K - Biologic Treatments in Moderate-to-Severe Ulcerative Colitis: Treatment Guidelines and Health Technology Assessments [H1]

- **Poster PSY127**: Hoge S, Brogan AP, Croft E - Orphan and Ultra-Orphan Technologies: European and Australian Payer Perceptions [P15]


5:45 – 6:45pm **Forum F7**: Hauber AB, Ijzerman M, Groothuis-Oudshoorn CG - Conjoint Analysis: Good Research Practices for Statistical Analysis [Brown 3 (L2)]

### Wed 11/11

**Poster Session V**
8:45am – 1:45pm


- **Poster PRM160**: Traina SB, McQuarrie K, Barrett A, DiBenedetti D, McLeod L - Content Validity of the Current Health Satisfaction Questionnaire (CHES-Q) Among People Living with Type 2 Diabetes Mellitus (T2DM) and Comorbid Chronic Kidney Disease (CKD) [F9]

- **Poster PRM232**: Stein D, Weatherall M, Garratt C, Aantaa R, Conti G, Lewis MA, Moore N, Gutthann S - Methodological Considerations for the Implementation of a European Mandated Retrospective Drug Utilisation Study (DUS) to Investigate the Use of Dexmedetomidine (DEXDOR®) in Clinical Practice [H29]

- **Poster PND70**: Poulos C, Kinter E, Posner J, Van Beek J - A Comparison of Stated Preferences for Injectable Disease-Modifying Treatments for Multiple Sclerosis: Compliant vs. Non-Compliant Patients [O8]

- **Poster PND71**: Mansfield CA, Thomas N, Gebben D - US RRMS Patient Preferences for Multiple Sclerosis Treatments: An Online Survey [O9]


8:45 – 9:45am **Workshop W20**: Gnanasakthy A, Doward L, Balv V, Fricke FU - How to Bring PRO Data into Payer Decision Making: PRO Strategies in Pharmaceutical Development [Brown 3 (L2)]

11:15am – 12:30pm **Plenary Session**: Ijzerman MJ, Marsh K, Hauber AB, Oliveira MD, Devlin N, Thokala P - Recommendations from the ISPOR Multi-Criteria Decision Analysis Emerging Good Practice Task Force and Remaining Controversies - Identification of Remaining Controversies and Solutions for Using MCDA in Health Care [Gold (L2)]
We’re always looking for great talent.

Health economists, outcomes researchers, statisticians, epidemiologists, business development professionals …

Submit your CV at our booth or send it to us at info@rtihs.org.